Research

Open Access

No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms

Thomas Burmeister*¹, Stefan Schwartz¹, Michael Hummel², Dieter Hoelzer³ and Eckhard Thiel¹

Address: ¹Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany,

²Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Institut für Pathologie, Hindenburgdamm 30, 12200 Berlin, Germany and

³Johann Wolfgang Goethe-Universität, Medizinische Klinik III, Theodor Stern-Kai 7, 60590 Frankfurt/Main, Germany

Email: Thomas Burmeister* - thomas.burmeister@charite.de; Stefan Schwartz - stefan.schwartz@charite.de;

Michael Hummel - michael.hummel@charite.de; Dieter Hoelzer - hoelzer@em.uni-frankfurt.de; Eckhard Thiel - haema.cbf@charite.de

* Corresponding author

Published: 7 February 2007

Received: 20 September 2006

Retrovirology 2007, **4**:11 doi:10.1186/1742-4690-4-11

Accepted: 7 February 2007

This article is available from: <http://www.retrovirology.com/content/4/1/11>

© 2007 Burmeister et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The Deltaretrovirus genus comprises viruses that infect humans (HTLV), various simian species (STLV) and cattle (BLV). HTLV-I is the main causative agent in adult T-cell leukemia in endemic areas and some of the simian T-cell lymphotropic viruses have been implicated in the induction of malignant lymphomas in their hosts. BLV causes enzootic bovine leukosis in infected cattle or sheep. During the past few years several new Deltaretrovirus isolates have been described in various primate species. Two new HTLV-like viruses in humans have recently been identified and provisionally termed HTLV-III and HTLV-IV. In order to identify a broad spectrum of Deltaretroviruses by a single PCR approach we have established a novel consensus PCR based on nucleotide sequence data obtained from 42 complete virus isolates (HTLV-I/-II, STLV-I/-II/-III, BLV). The primer sequences were based on highly interspecies-conserved virus genome regions. We used this PCR to detect Deltaretroviruses in samples from adult patients with a variety of rare T-cell neoplasms in Germany.

Results: The sensitivity of the consensus PCR was at least between 10^{-2} and 10^{-3} with 100% specificity as demonstrated by serial dilutions of cell lines infected with either HTLV-I, HTLV-II or BLV. Fifty acute T-cell lymphoblastic leukemia (T-ALL) samples and 33 samples from patients with various rare mature T-cell neoplasms (T-PLL, Sézary syndrome and other T-NHL) were subsequently investigated. There were no cases with HTLV-I, HTLV-II or any other Deltaretroviruses.

Conclusion: The results rule out a significant involvement of HTLV-I or HTLV-II in these disease entities and show that other related Deltaretroviruses are not likely to be involved. The newly established Deltaretrovirus PCR may be a useful tool for identifying new Deltaretroviruses.

Background

Retroviruses are the main etiologic agents in a variety of malignant diseases in animals [1]. Bovine leukemia virus

(BLV) was the first Deltaretrovirus to be discovered in 1969 by electron microscopy [2], but it was not until 1985 that the first complete nucleotide sequence of an isolate

Table 1: Accession number of the 42 virus isolates used in the nucleotide sequence alignments.

Virus	EMBL/Genbank/DBJ accession number
HTLV-I	[EMBL:AY563954] (Brazilian isolate), [EMBL:AY563953] (Brazilian isolate), [GenBank:NC_001436], [EMBL:AF259264] (isolate WHP from China), [EMBL:AF139170] (from an HTLV-I/II seroindeterminate patient), [EMBL:J02029] (Japanese ATL isolate), [EMBL:AF033817], [EMBL:L03561], [EMBL:D13784] (Caribbean isolate), [EMBL:L02534] (Melanesian isolate), [EMBL:U19949] (isolate from an ATL patient), [EMBL:AF042071] (isolate from Germany), [EMBL:L36905] (from a patient with post-transfusion spastic paraparesis)
HTLV-II	[GenBank:NC_001488], [EMBL:AF326584] (Brazilian isolate), [EMBL:AF326583] (Brazilian isolate, strain RP329), [EMBL:AF412314] (with HIV coinfection), [EMBL:AF139382] (Brazilian isolate), [EMBL:AF074965] (isolate from a Guahibo Indian from Venezuela), [EMBL:M10060], [EMBL:L11456] (Guyami Indian isolate), [EMBL:Y14365] (Congolese Bambute Efe Pygmy isolate), [EMBL:X89270] (Italian isolate), [EMBL:L20734], [EMBL:Y13051] (African isolate, subtype b)
STLV-I	[GenBank:NC_000858] (from a naturally infected tamarin monkey from Central Africa), [EMBL:AY590142] (in <i>Macaca arctoides</i>), [EMBL:Z46900] (from Celebes macaques), [EMBL:AF074966] (isolate Tan90 from Central African Republic)
STLV-II	[GenBank:NC_001815], [EMBL:Y14570] (STLV-PP from <i>Pan paniscus</i>), [EMBL:U90557] (from <i>Pan paniscus</i>)
STLV-III	[EMBL:AF517775] (from <i>Papio hamadryas papio</i> from Senegal), [GenBank:NC_003323] (from red-capped mangabeys (<i>Cercocebus torquatus</i>) from Cameroon), [EMBL:AY217650] (from <i>Theropithecus gelada</i>), [EMBL:AY222339] (from a red-capped mangabey – <i>Cercocebus torquatus torquatus</i> – from Nigeria), [EMBL:Y07616] (STLV-PH969 from a <i>Hamadryas baboon</i>)
BLV	[GenBank:NC_001414], [EMBL:AF257515] (from a Holstein cow from Argentina), [EMBL:K02120] (Japanese isolate), [EMBL:AF033818], [EMBL:D00647] (Australian isolate)

was reported [3]. Since the discovery of HTLV-I [4] and HTLV-II [5] and their closely related simian counterparts STLV-I [6] and STLV-II [7] several Deltaretrovirus isolates have been described in various non-human primate species. In 1994, a third simian Deltaretrovirus, later designated as STLV-III, was identified in a *Hamadryas Baboon* (*Papio Hamadryas*) [8-10]. Until recently no human counterparts of STLV-III were known, but in 2005 two independent research groups described human isolates that showed high homology to STLV-III and were considered to be HTLV-III isolates [11,12]. Moreover, a fourth Deltaretrovirus was identified in a single human individual from the Rain Forest in Cameroon. It did not show sufficient homology to be classified as primate T-cell lymphotropic virus (PTLV) type I, II or III and was thus considered to be a species representative of a hitherto unknown putative PTLV-IV virus group [12].

HTLV-I and STLV-I are etiologically linked to the induction of certain T-cell lymphomas/leukemias in their hosts [13,14]. The oncogenic action of the virus is mediated by

the viral *tax* and *rex* genes that act as transcription factors, thereby promoting cell growth and malignant transformation. However, the etiology of many human malignant T-cell and T-/NK-cell disorders is still not well understood. On the other hand a great deal of knowledge has been gained in the last years on the molecular biology of Deltaretroviruses, since a large number of new isolates have been described. To investigate the possible involvement of Deltaretroviruses in various human T-cell neoplasms, we have constructed a novel Deltaretrovirus consensus PCR based on nucleotide sequence alignments of all 42 complete Deltaretrovirus isolates published to date. Highly conserved virus genome regions were identified that allowed the construction of a generic PCR, capable of detecting all known Deltaretroviruses.

Results

A total of 42 complete Deltaretrovirus isolates could be retrieved from the EMBL/Genbank/DBJ nucleotide sequence database (Table 1). These included 13 HTLV-I, 12 HTLV-II, 4 STLV-I, 3 STLV-II, 5 STLV-III, and 5 BLV iso-

Table 2: Patient and disease characteristics.

Disease entity (N)	N	Median age (range) [years]
Precursor T-cell (50)	Early T-cell lymphoblastic Cortical (thymic) T-cell lymphoblastic	11 31 34 (17–63)
Mature T-cell (31)	Mature T-cell lymphoblastic T-prolymphocytic Sézary syndrome and Mycosis fungoides Ki-1 large T-cell lymphoma Intestinal T-cell lymphoma Other (unspecified) peripheral T-NHL	8 16 5 3 1 6 65 (48–83)
NK cell disorders (2)	LGL leukemia	2 29 and 78

M10060	CAATTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
NC_001488	CAATTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
AF412314	CAATTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
AF139382	CAATTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
AF326584	CAATTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
AF326583	CAATTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
L20734	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
Y13051	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
L11456	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
X89270	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
AF074965	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
Y14365	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
Y14570	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
NC001815	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
U90557	CAAGTGGGGG	CTCGTCCGGG...TTAAACCTGA	GCGCCTCCAG	GCC
Y07616	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF217650	CAGGTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF517775	CAGGTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCT
AF222339	CAGGTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
NC_003323	CAGGTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
L36905	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF139170	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF042071	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
L03561	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF259264	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AY563953	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AY563954	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
U19949	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
J02029	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
D13748	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF033817	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
NC_001436	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AF074966	CAGGTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
NC_000858	CAGGTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
L02534	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
Z46900	CAGTTGGGGG	CTCGTCCGGG...TTAAACCGGA	ACGCCTCCAG	GCC
AY590142	CAGTTGGGGG	CTCGTCCGGG...TTAAACCTGA	ACGCCTCCAG	GCC
AF033818	CAATTGGGGG	CTCGTCCGGG...TTAAACTAGA	ACGCCTCCAG	GCC
NC_001414	CAATTGGGGG	CTCGTCCGGG...TTAAACTAGA	ACGCCTCCAG	GCC
K02120	CAATTGGGGG	CTCGTCCGGG...TTAAACTAGA	ACGCCTCCAG	GCC
D00647	CAATTGGGGG	CTCGTCCGGG...TTAAACTAGA	ACGCCTCCAG	GCC
AF257515	CAATTGGGGG	CTCGTCCGGG...TTAAACTAGA	ACGCCTCCAG	GCC
consensus	CARKTGGGGG	CTCGTCCGGG...	AAATTGGRHCT	YCGGAGGTCG CGG

Figure 1

PCR primer regions with consensus primers. The accession numbers of the different isolates are given on the left. The first region corresponds to the proline tRNA binding site; the start of the *pol* ORF is underlined in the second region (site of ribosomal frameshift).

lates. A common feature of the Deltaretrovirus genus is the use of proline tRNA as a primer for the complementary minus-strand DNA synthesis. tRNA genes are highly conserved between different species [15]. Alignment of the collected sequences showed a very high degree of conservation of this functionally important region. Additionally, a second highly conserved region was identified approximately 1.8 kb 3' of the tRNA binding site (Fig. 1). The *pol* ORF of HTLV-I/-II/BLV is expressed by using two ribosomal -1 frame shifts, and the second frame shift with the transcription start site of the *pol* ORF lies within this region [1]. The high degree of conservation of this region is thus understandable. A phylogenetic tree constructed from the aligned region illustrates the genetic relationships (Fig. 2). No other genomic regions with a similarly high degree of conservation were identified (see Additional File 1). Degenerate primers complementary to these regions were constructed (Fig. 1). The degeneracy of the primers was moderate (4-fold for (+) and 12-fold for (-)). The PCR was tested using serial dilutions of Deltaretrovirus-infected cell line DNA in human leukocyte DNA under various conditions (Fig. 3). Retrovirus-infected cell

lines frequently harbor more than one copy of the virus, although often some of these copies are defective. When calculating PCR sensitivity this factor has to be taken into account. The HTLV-I/HTLV-II/BLV copy number has been determined in various cell lines which revealed copy numbers between 1 and 17 per cell [16-18]. We thus assumed a sensitivity of 10^{-2} – 10^{-3} for our PCR. This sensitivity appeared highly sufficient for our purpose. The PCR produced a faint 657 bp sideband when testing human DNA or cell line DNA diluted in human DNA (Fig. 3). Cloning and sequencing of the 657 bp product (EMBL nucleotide sequence database Acc No [EMBL:AM422011]) and a successive BLAST search revealed that it originated from amplification of a sequence on chromosome 3 (Acc No [EMBL:AC114481], Ncl 81342-80686) and 11 (Acc No [EMBL:AP000785], Ncl 74948-75403) by primer *delta-F*.

It should be noted that the PCR sensitivity could be further increased to 10^{-3} – 10^{-4} (while retaining specificity) by lowering the annealing temperature to 60°C and increasing the number of PCR cycles but at the expense of a stronger 657 bp sideband.

A total of 83 samples were obtained from patients with various rare mature T-cell (N = 31) and precursor T-cell neoplasms (N = 50) and from 2 patients with NK-cell disorders. All samples had been thoroughly characterized immunologically and genetically and contained a high percentage ($\geq 50\%$) of malignant cells (Table 2). All samples were fresh (i.e. unfixed) tumor material, and the DNA quality was ensured by various control PCRs.

None of the investigated samples yielded a PCR product indicative of the presence of a Deltaretrovirus. The parallel investigation of positive controls led to the expected results.

Discussion

While the etiological involvement of HTLV-I in endemic adult T-cell leukemia/lymphoma is beyond dispute there have been repeated controversies whether this virus might also play a role in other T-cell neoplasms such as T-prolymphocytic leukemia [19], Sézary syndrome or Mycosis fungoides [20-22]. The situation is further complicated by the fact that the classification of T-NHLs has been evolving and changing over the years as new disease entities are recognized and refined diagnostic criteria are established [23,24]. Thus the results of older studies may not always be fully transferable to today's situation. Some investigators have also suggested that a truncated HTLV-I may play a role in certain T-NHLs [19,25]. On the other hand HTLV-II has not been convincingly linked to any specific malignant T-cell disorder. The simian Deltaretroviruses are implicated in lymphomatous diseases in various simian hosts (reviewed in [1]). The newly discovered HTLV-

Figure 2

Phylogenetic tree based on the nucleotide sequence alignment of the amplified region. The recently described HTLV-III and HTLV-IV isolates are not included since no complete isolates have been published yet. The tree is not intended to set up a phylogeny but to illustrate the genetic relationships between the isolates.

III and HTLV-IV isolates have not yet been fully characterized, and their distribution or possible involvement in human disease is unknown.

A few previous investigations performed on precursor T-cell neoplasms in Germany were mainly based on HTLV-I serology [26] which may not be as reliable as nucleic acid-based techniques [27]. Germany has a low HTLV-I seroprevalence, but virus isolates without linkage to endemic areas have occasionally been reported [28].

The causes of most malignant T-cell disorders are only partially understood. Numerous recurrent genetic aberrations have been described [29] but a clear and detailed model of disease development still does not exist. Oncogenic viruses such as Epstein-Barr virus or HTLV-I are well established causative factors in various human T-cell lymphomas and leukemias [29]. It appears possible that yet undetected Deltaretroviruses may play a role in human T-cell malignancies.

We developed a consensus PCR for detecting Deltaretroviruses based on highly conserved genomic sequences of all published complete Deltaretrovirus isolates. Since this PCR is based on highly interspecies conserved sequence motifs it may also be capable of detecting related but hitherto unknown Deltaretroviruses. However, despite high sensitivity and specificity of our PCR approach, no Del-

taretrovirus-positive cases were found in our series of samples.

Conclusion

The results rule out a role of known Deltaretroviruses in the disease entities under investigation here. The involvement of a hitherto undetected Deltaretrovirus is not completely excluded but rendered more unlikely. Truncated proviruses that have lost their 5'-region with the tRNA binding site may also escape detection by our PCR system. Despite these negative results, our newly established consensus PCR may be a useful tool in the search for and characterization of new Deltaretroviruses in primates and other mammals.

Methods

Cell lines

The following cell lines were used: *BL3.1* (infected with BLV, a bovine lymphoma cell line, [30]), *MJ [G11]* (infected with HTLV-I, derived from a human cutaneous T-cell lymphoma, [31]) and *Mo T* (infected with HTLV-II, derived from a patient with hairy cell leukemia, [32]). All cell lines were obtained from the ATCC (Acc No CRL-2306, TIB-8294, and TIB-8066, respectively). Cell culture was done according to the recommendations of the supplier. DNA isolated from the cell lines was used to prepare serial dilution rows.

DNA isolation

DNA was isolated from sample material or cell lines using the *PureGene* kit (Biozym Diagnostik, Hessisch Oldendorf/Germany) and dissolved in Tris/EDTA buffer at a concentration of 60 ng/μl.

Preparation of cell line dilution series

Serial dilutions of cell line DNA in DNA from buffy coats of blood donors were prepared as recently described [33].

Patient samples

All samples were obtained for diagnostic purposes, and we retrospectively investigated archived material. The patients had given their consent for scientific investigations. The T-precursor samples were obtained within the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL). Our study complied with the Helsinki Declaration.

PCR method

The HotStarTaq kit (QIAGEN, Hilden/Germany) was used with 200 ng sample DNA, 400 nM of each PCR primer *delta-F* 5'-CARKTGGGGGCTCGTCCGGGAT-3' and *delta-R* 5'-GGCCTGGAGGCGYTCHRGTTTAA-3', buffer conditions and polymerase mix as recommended by the supplier. The primers were optimized derivatives of those previously published [34] and HPLC-purified. The follow-

Figure 3

Deltaretrovirus PCR tested in serial dilutions of cell lines. Cell line DNA was diluted in genomic DNA from healthy individuals. **A:** cell line *Mo T* (HTLV-II-infected), **B:** cell line *Mj* (HTLV-I-infected), **C:** cell line *BL3.1* (BLV-infected). First and last lane in every gel: ϕ X174/*Hae* III size standard (QIAGEN, Hilden/Germany). No cell line harboring STLV-III, HTLV-III or HTLV-IV is currently available. All cell lines yield a PCR product of approximately 1.8 kb. A small sideband at 657 bp is visible which could serve as an internal control for DNA integrity.

ing cycler program was used on a GeneAmp 2400 Cycler (PerkinElmer): 94°C for 15 minutes, 40 cycles (94°C for 20 seconds, 62°C for 20 seconds, 72°C for 90 seconds), 4°C.

Nucleotide sequence alignments

All available complete nucleotide sequences from Delta retrovirus isolates were collected from the EMBL/Genbank/DDBJ database (Table 1), converted into FASTA file format, and aligned using the ClustalX software [35].

Phylogenetic analysis

The PHYLIP program package [36], version 3.65 for MacOS X, with the program modules *dnacomp* and *drawgram* was used with the default parameters to construct a phylogenetic tree from the aligned sequences.

Immunophenotyping

Immunophenotyping by FACS analysis was done essentially by standard methods described elsewhere [37].

Abbreviations

HTLV human T-cell lymphotropic virus

STLV simian T-cell lymphotropic virus

BLV bovine leukemia virus

PTLV primate T-cell lymphotropic virus

PCR polymerase chain reaction

PLL prolymphocytic leukemia

NHL Non Hodgkin lymphoma

ALL acute lymphoblastic leukemia

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

TB designed and performed the laboratory work, particularly the PCR, did the alignments and phylogenetic analysis and wrote the paper. SS and ET performed immunophenotyping of samples. MH characterized specific samples by analysis of T-cell receptor clonality. DH is chairman of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) which provided the T-ALL samples. All authors have read and approved the manuscript.

Additional material

Additional File 1

contains an alignment of the 42 retrovirus sequences from Table 1 (the genome region between primer delta-F and delta-R).

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1742-4690-4-11-S1.pdf>]

Acknowledgements

The authors are grateful to Mara Molkentin, Barbara Komischke and Rita Lippoldt for their skillful technical assistance. They are indebted to Prof. Harald Stein (Head of the Dept. of Pathology, Charité Campus Benjamin Franklin) for giving them access to lymphoma DNA samples. TB and SS were supported by the Deutsche Krebshilfe (German Cancer Aid, grant I0-1988-Bu1). TB is also supported by the Berliner Krebsgesellschaft (Berlin Cancer Society). Dr. J. Weirowski critically read the manuscript.

References

- Coffin JM, Hughes SH, Varmus HE, (Eds): *Retroviruses* New York: Cold Spring Harbor Laboratory Press; 1997.
- Miller JM, Miller LD, Olson C, Gillette KG: **Virus-like particles in phytohemagglutinin-stimulated lymphocyte cultures with reference to bovine lymphosarcoma.** *J Natl Cancer Inst* 1969, **43**:1297-1305.
- Sagata N, Yasunaga T, Tsuzuku-Kawamura J, Ohishi K, Ogawa Y, Ikawa Y: **Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses.** *Proc Natl Acad Sci USA* 1985, **82**:677-681.
- Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC: **Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia.** *Nature* 1981, **294**:268-271.
- Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC: **A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia.** *Science* 1982, **218**:571-573.
- Miyoshi I, Yoshimoto S, Fujishita M, Taguchi H, Kubonishi I, Niiya K, Minezawa M: **Natural adult T-cell leukemia virus infection in Japanese monkeys.** *Lancet* 1982, **2**:658.
- Chen YAM, Jang YJ, Kanki PJ, Yu QC, Wang JJ, Montali RJ, Samuel KP, Papas TS: **Isolation and characterization of simian T-cell leukemia virus type II from new world monkeys.** *J Virol* 1994, **68**:1149-1157.
- Goubau P, Van Brussel M, Vandamme A-M, Liu HF, Desmyter J: **A primate T-lymphotropic virus, PTLV-L, different from human T-lymphotropic viruses types I and II, in a wild-caught baboon.** *Proc Natl Acad Sci USA* 1994, **91**:2848-2852.
- Van Brussel M, Goubau P, Rousseau R, Desmyter J, Vandamme AM: **The genomic structure of a new simian T-lymphotropic virus, STLV-ph969, differs from that of human T-lymphotropic virus types I and II.** *J Gen Virol* 1996, **77**:347-358.
- Van Brussel M, Salemi M, Liu MH-F, Gabriels J, Goubau P, Desmyter J, Vandamme AM: **The simian T-lymphotropic virus STLV-PPI664 from Pan paniscus is distinctly related to HTLV-II but differs in genomic organization.** *Virology* 1999, **243**:366-379.
- Calattini S, Chevalier SA, Duprez R, Bassot S, Froment A, Mahieux R, Gessain A: **Discovery of a new human T-cell lymphotropic virus (HTLV-III) in Central Africa.** *Retrovirology* 2005, **2**:30.
- Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, Torimiro JN, Prosser AT, Lebreton M, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, Burke DS, Switzer WM: **Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters.** *Proc Natl Acad Sci USA* 2005, **102**:7994-7999.
- Gallo RC: **The discovery of the first human retrovirus: HTLV-I and HTLV-II.** *Retrovirology* 2005, **2**:17.

14. Allan JS, Leland M, Broussard S, Mone J, Hubbard G: **Simian T-cell lymphotropic Viruses (STLVs) and lymphomas in African nonhuman primates.** *Cancer Invest* 2001, **19**:383-395.
15. Sprinzl M, Horn C, Brown M, Ioudovitch A, Steinberg S: **Compilation of tRNA sequences and sequences of tRNA genes.** *Nucleic Acids Res* 1998, **26**:148-153.
16. Albrecht B, Collins ND, Newbound GC, Ratner L, Lairmore MD: **Quantification of human T-cell lymphotropic virus type I proviral load by quantitative competitive polymerase chain reaction.** *J Virol Methods* 1998, **75**:123-140.
17. Murphy EL, Lee TH, Chafets D, Nass CC, Wang B, Loughlin K, Smith D, HTLV Outcomes Study Investigators: **Higher human T lymphotropic virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with HTLV-II subtype A versus B, and with male sex and a history of blood transfusion.** *J Infect Dis* 2004, **190**:504-10.
18. Van den Broeke A, Cleuter Y, Beskorwayne T, Kerkhofs P, Szyal M, Bagnis C, Burny A, Griebel P: **CD154 costimulated ovine primary B cells, a cell culture system that supports productive infection by bovine leukemia virus.** *J Virol* 2001, **75**:1095-103.
19. Kojima K, Sawada T, Ikezoe T, Matsuo Y, Kobayashi H, Yano T, Sugimoto T, Imoto S, Nakagawa T, Matsui T, Yasukawa M, Hara M, Taguchi H: **Defective human T-lymphotropic virus type I provirus in T-cell prolymphocytic leukaemia.** *Br J Haematol* 1999, **105**:376-381.
20. Zucker-Franklin D, Pancake BA, Marmor M, Legler PM: **Reexamination of human T cell lymphotropic virus (HTLV-I/II) prevalence.** *Proc Natl Acad Sci USA* 1997, **94**:6403-6407.
21. Shohat M, Hodak E, Hannig H, Bodemer W, David M, Shohat B: **Evidence for the cofactor role of human T-cell lymphotropic virus type I in mycosis fungoides and Sézary syndrome.** *Br J Dermatol* 1999, **141**:44-49.
22. Sakamoto FH, Colleoni GW, Teixeira SP, Yamamoto M, Michalany NS, Almeida FA, Chiba AK, Petri V, Fernandes MA, Pombo-de-Oliveira MS: **Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma.** *Int J Dermatol* 2006, **45**:447-449.
23. Jaffe ES, Harris NL, Stein H, Vardiman JW, (Eds): *Pathology and genetics of Tumours of Haematopoietic and Lymphoid Tissues* Lyon: IARC Press; 2001.
24. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D: **A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories.** *Blood* 2004, **104**:328-335.
25. Morozov VA, Syrtsev AV, Ellerbrok H, Nikolaeva EV, Bavykin AS, Pauli G: **Mycosis fungoides in European Russia: no antibodies to human T cell leukemia virus type I structural proteins, but virus-like sequences in blood and saliva.** *Intervirology* 2005, **48**:362-371.
26. Dölken G, Bross KJ, Chosa T, Schneider J, Bayer H, Hunsmann G: **No evidence for HTLV infection among leukaemia patients in Germany.** *Lancet* 1983, **2**:1495.
27. Miyoshi I, Hatakeyama N, Murakami K, Sawada T, Takimoto Y: **Sézary syndrome in an HTLV-I-seronegative, genome-positive Japanese.** *Am J Hematol* 1998, **57**:184-185.
28. Ellerbrok H, Fleischer C, Salemi M, Reinhardt P, Ludwig WD, V�ndamme AM, Pauli G: **Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas.** *AIDS Res Hum Retroviruses* 1998, **14**:1199-1203.
29. Jaffe ES, Harris NL, Stein H, Vardiman JW: *Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues* Lyon: IARC Press; 2001.
30. Harms JS, Splitter GA: **Impairment of MHC class I transcription in a mutant bovine B cell line.** *Immunogenetics* 1992, **35**:1-8.
31. Popovic M, Sarin PS, Robert-Gurroff M, Kalyanaraman VS, Mann D, Minowada J, Gallo RC: **Isolation and transmission of human retrovirus (human t-cell leukemia virus).** *Science* 1983, **219**:856-859.
32. Saxon A, Stevens RH, Quan SG, Golde DW: **Immunologic characterization of hairy cell leukemias in continuous culture.** *J Immunol* 1978, **120**:777-782.
33. Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S, Hoelzer D, Thiel E: **Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.** *Leukemia* 2006, **20**:451-457.
34. Burmeister T, Schwartz S, Thiel E: **A PCR primer system for detecting oncoretroviruses based on conserved DNA sequence motifs in animal retroviruses and its application to human leukaemias and lymphomas.** *J Gen Virol* 2001, **82**:2205-2213.
35. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: **The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.** *Nucleic Acids Research* 1997, **24**:4876-4882.
36. Felsenstein J: *Inferring Phylogenies* Sunderland (Massachusetts): Sinauer Associates; 2004.
37. Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S: **NUP214-ABL1 in adult T-ALL: the GMALL study group experience.** *Blood* 2006, **108**:3556-3559.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp